Suppr超能文献

中国上海 COVID-19 患者的临床进展。

Clinical progression of patients with COVID-19 in Shanghai, China.

机构信息

Department of Infectious Diseases and Immunology, Shanghai Public Health Clinical Center, Shanghai 201508, China.

Department of Infectious Diseases, Shanghai Public Health Clinical Center, 2901 Caolang Road, Shanghai 201508, China.

出版信息

J Infect. 2020 May;80(5):e1-e6. doi: 10.1016/j.jinf.2020.03.004. Epub 2020 Mar 19.

Abstract

BACKGROUND

Studies on the 2019 novel coronavirus disease (COVID-19) have generally been limited to the description of the epidemiology and initial clinical characteristics. We investigated the temporal progression in patients with COVID-19.

METHODS

In this retrospective, single-center study, we included confirmed cases of COVID-19 from Jan 20 to Feb 6, 2020 in Shanghai. Final date of follow-up was February 25, 2020.

RESULTS

Of the 249 patients enrolled, the median age was 51 years old, and 126 (50.6%) were male. The duration from onset of symptoms to hospitalization was 4(2-7) days in symptomatic patients. Fever was occurred in 235(94.3%) patients. A total of 215 (86.3%) patients had been discharged after 16(12-20) days hospitalization. The estimated median duration of fever in all the patients with fever was 10 days (95 confidential intervals [CIs]: 8-11 days) after onset of symptoms. Patients who were transferred to intensive care units (ICU) had significantly longer duration of fever as compared to those not in ICU (31 days v.s. 9 days after onset of symptoms, respectively, P <0.0001). Radiological aggravation of initial image was observed in 163 (65.7%) patients on day 7 after onset of symptoms. 154(94.5%) of these patients showed radiological improvement on day 14. The median duration to negative reverse-transcriptase PCR tests of upper respiratory tract samples was 11 days (95 CIs: 10-12 days). Viral clearance was more likely to be delayed in patients in ICU than those not in ICU (P <0.0001). In multivariate logistical analysis, age (Odds ratio [OR] = 1.06) and CD4 T cell count (OR = 0.55 per 100 cells/ul increase) were independently associated with ICU admission.

CONCLUSIONS

The majority of COVID-19 cases are mild. The clinical progression pattern suggests that early control of viral replication and application of host-directed therapy in later stage is essential to improve the prognosis of CVOID-19.

摘要

背景

关于 2019 年新型冠状病毒病(COVID-19)的研究通常仅限于描述其流行病学和初始临床特征。我们调查了 COVID-19 患者的时间进展情况。

方法

在这项回顾性的单中心研究中,我们纳入了 2020 年 1 月 20 日至 2 月 6 日上海确诊的 COVID-19 病例。最终随访日期为 2020 年 2 月 25 日。

结果

在纳入的 249 例患者中,中位年龄为 51 岁,126 例(50.6%)为男性。有症状患者从出现症状到住院的时间为 4(2-7)天。235 例(94.3%)患者发热。16(12-20)天后,215 例(86.3%)患者出院。所有发热患者的发热中位持续时间为症状出现后 10 天(95%置信区间:8-11 天)。与未转入重症监护病房(ICU)的患者相比,转入 ICU 的患者发热时间明显延长(分别为症状出现后 31 天和 9 天,P<0.0001)。在症状出现后第 7 天,163 例(65.7%)患者的初始图像出现影像学加重。其中 154 例(94.5%)患者在第 14 天出现影像学改善。上呼吸道样本逆转录酶聚合酶链反应检测结果阴性的中位时间为 11 天(95%置信区间:10-12 天)。与未转入 ICU 的患者相比,转入 ICU 的患者病毒清除时间更可能延迟(P<0.0001)。在多变量逻辑分析中,年龄(优势比[OR] = 1.06)和 CD4 T 细胞计数(OR = 每增加 100 个细胞/μl 降低 0.55)与 ICU 入院独立相关。

结论

大多数 COVID-19 病例为轻症。临床进展模式表明,早期控制病毒复制和后期应用宿主定向治疗对于改善 COVID-19 预后至关重要。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1139/7102530/9b27f28c2a96/gr1_lrg.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验